We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.96%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.51B
AUM Growth
+$152M
Cap. Flow
+$148M
Cap. Flow %
9.78%
Top 10 Hldgs %
81.92%
Holding
39
New
5
Increased
6
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$172M
2
ANNX icon
Annexon
ANNX
+$25.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.1M
4
ALXO icon
ALX Oncology
ALXO
+$8.95M
5
PRME icon
Prime Medicine
PRME
+$6.05M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$30M
2
COGT icon
Cogent Biosciences
COGT
+$27.7M
3
REPL icon
Replimune Group
REPL
+$10.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$7.41M
5
NRIX icon
Nurix Therapeutics
NRIX
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LIVN icon
26
LivaNova
LIVN
$4.41B
$6.89M 0.46%
108,354
-9,700
-8% -$626K
ESTA icon
27
Establishment Labs
ESTA
$2.14B
$5.87M 0.39%
103,464
-9,200
-8% -$628K
PRME icon
28
Prime Medicine
PRME
$660M
$5.54M 0.37%
+1,590,832
New +$6.05M
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.42B
$5.27M 0.35%
415,710
-32,400
-7% -$368K
EPRX
30
Eupraxia Pharmaceuticals
EPRX
$486M
$5.07M 0.34%
+700,000
New +$5.63M
ARDX icon
31
Ardelyx
ARDX
$986M
$4.39M 0.29%
+733,350
New +$4.85M
IVVD icon
32
Invivyd
IVVD
$265M
$3.44M 0.23%
2,648,659
-32,500
-1% -$59.7K
ATRA icon
33
Atara Biotherapeutics
ATRA
$92.8M
$2.09M 0.14%
441,701
– –
AGMB
34
AgomAb Therapeutics NV
AGMB
$682M
$1.64M 0.11%
+156,250
New +$2.21M
PLRX icon
35
Pliant Therapeutics
PLRX
$71.2M
$973K 0.06%
772,126
-844,102
-52% -$1.07M
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
– –
-885,927
Closed -$30M
REPL icon
37
Replimune Group
REPL
$1.47B
– –
-1,099,756
Closed -$10.7M
RPTX
38
DELISTED
Repare Therapeutics
RPTX
– –
-1,586,174
Closed -$4.12M
KLRS
39
Kalaris Therapeutics
KLRS
$97.6M
– –
-82,955
Closed -$700K
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2026 Portfolio in Review

As of Q1 2026, Redmile Group held 39 positions worth $1.51B, up 11% from $1.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Redmile Group deployed $148M of net new capital in Q1 2026, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $27.7M trimmed.

  • Redmile Group's largest Q1 2026 buy was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.
  • Redmile Group added most to Scholar Rock in Q1 2026, an estimated $172M increase.
  • Redmile Group's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $27.7M.
  • Redmile Group fully exited RAPT Therapeutics in Q1 2026, selling an estimated $30M.
  • Redmile Group's ten largest holdings make up 82% of its $1.51B portfolio in Q1 2026.
  • Redmile Group opened 5 new positions and closed 4 in Q1 2026.
  • Redmile Group's portfolio value rose 11% quarter-over-quarter to $1.51B.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.